A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Giredestrant (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; LHRH receptor agonists
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms acelERA BC
- Sponsors Roche
- 22 Jun 2024 Planned End Date changed from 27 Jun 2024 to 27 Jun 2025.
- 29 Jan 2024 Planned End Date changed from 27 Mar 2024 to 27 Jun 2024.
- 01 Nov 2023 Planned End Date changed from 27 Nov 2023 to 27 Mar 2024.